Oral dabigatran etexilate versus enoxaparin for venous thromboembolism prevention after total hip arthroplasty: pooled analysis of two phase 3 randomized trials

Thrombosis Journal

Original Clinical Investigation

Andreas Clemens¹  Martin Feuring²  Jörg Kreuzer²  Nadia Rosencher³  Bengt I. Eriksson⁴  Richard J. Friedman⁵  Stefan Hantel⁶  Ola E. Dahl⁷  Michael Huo⁸ 

[1] Corporate Department of Medical Affairs, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany;Center of Thrombosis, University Hospital Mainz, Mainz, Germany;Corporate Department of Medical Affairs, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany;Department of Medicine, University of Heidelberg, Heidelberg, Germany;Department of Anaesthesiology and Intensive Care, Paris Descartes University, Cochin Hospital (AP HP), Paris, France;Department of Orthopaedics, Sahlgrenska University Hospital, SE 413 45, Gothenburg, Sweden;Department of Orthopedics, Medical University of South Carolina, Charleston, SC, USA;Medical Data Services, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany;Thrombosis Research Institute, Emmanuel Kaye Building, Manresa Road, London, UK;Innlandet Hospital Trust, Brumunddal, Norway;University of Texas Southwestern Medical Center, Dallas, TX, USA;

关键词: Arthroplasty;    Bleeding;    Enoxaparin;    Dabigatran;    Deep vein thrombosis;    Mortality;    Prophylaxis;    Pulmonary embolism;    Venous thromboembolism;   

DOI  :  10.1186/s12959-015-0067-8

 received in 2015-07-16, accepted in 2015-08-06,  发布年份 2015

来源: Springer

【 摘 要 】

BackgroundTwo phase 3 trials compared 28–35 days of treatment with oral dabigatran 220 mg or 150 mg (RE-NOVATE) or 220 mg (RE-NOVATE II) once daily with subcutaneous enoxaparin 40 mg once daily for prevention of venous thromboembolism (VTE) after elective total hip arthroplasty.MethodsThis prespecified pooled analysis compared the outcomes for the dabigatran 220 mg dose with enoxaparin, which included 4,374 patients. Total VTE (venographic and symptomatic) plus all-cause mortality (primary efficacy), major VTE (proximal deep vein thrombosis [DVT] or non-fatal pulmonary embolism) plus VTE-related death, and bleeding events were evaluated. Efficacy analysis was based on the modified intention-to-treat (ITT) population and safety analysis was based on all treated patients. The common risk difference (RD) for dabigatran versus enoxaparin was estimated using a fixed effects model.ResultsTotal VTE and all-cause mortality occurred in 6.8 % (114/1,672) and 7.7 % (129/1,682) (RD:–0.8 %, 95 % confidence interval [CI] –2.6 to 0.9) for dabigatran and enoxaparin, respectively. Major VTE plus VTE-related mortality occurred in 2.7 % (46/1,714) and 4.0 % (69/1,711) (RD: –1.4 %, 95 % CI –2.6 to –0.2) of patients receiving dabigatran 220 mg and enoxaparin, respectively. Major bleeding occurred in 1.7 % (37/2,156) and 1.3 % (27/2,157) (RD: 0.5 %, 95 % CI –0.2 to 1.2), for dabigatran and enoxaparin respectively.ConclusionsExtended prophylaxis with oral dabigatran 220 mg once daily was as effective as enoxaparin 40 mg once daily in reducing the risk of total VTE and all-cause mortality after total hip arthroplasty, with a similar bleeding profile. The clinically relevant outcome of major VTE and VTE-related death was significantly reduced with dabigatran versus enoxaparin.Trial registrationNCT00657150 and NCT00168818

【 授权许可】

CC BY   
© Eriksson et al. 2015